According to the NCI website seliciclib is an orally bioavailable, small-molecule cyclin-dependent kinase (CDK) inhibitor with potential proapoptotic and antineoplastic activities.

Link to Drug Information Portal
Link to MedlinePlus
Link to National Cancer Institute
Link zu Wiki

Cyclin-dependent-kinases